Report: Guidant considered warning doctorsJun 7, 2006 | UPI
The Guidant Corp. reportedly considered warning physicians last year about serious defects found in some heart defibrillators produced by the company.
Guidant executives have defended their decision not to warn physicians about the defects because doing so might have placed patients at risk for unnecessary device replacement, The New York Times reported Wednesday.
But newly released company records from January 2005 indicate the company drafted a letter to physicians in which the Minnesota-headquartered Guidant warns of defects in two of its defibrillators. The letter informs physicians the company had recalled all of the affected devices that had not yet been implanted.
But the letter was never sent and more heart patients received the defibrillators known as the Contak Renewal and Contak Renewal 2, The Times said.
The draft letter and other records released this week by a Texas state judge might have legal and financial consequences for the Massachusetts-based Boston Scientific Corp., which acquired Guidant in April, the newspaper reported.